Ceapro Announces Acceptance of Abstract for Presentation at the Nutrition 2018 Meeting
EDMONTON, Alberta, April 03, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the American Society for Nutrition’s inaugural flagship meeting, Nutrition 2018, being held at the Hynes Convention Center from June 9-12, 2018 in Boston, MA.
Tianou Zhang MD, MS, PhD Candidate, at the Laboratory of Physiological Hygiene and Exercise Science, School of Kinesiology at University of Minnesota, will give an oral presentation of the accepted abstract titled, “Oat Avenanthramides Protects Against Eccentric Exercise Induced Muscle Inflammation in Human after Downhill Running,” on Tuesday, June 12, 2018 at 10:30 a.m. EDT as a part of the Anti-Inflammation Effect of Dietary Bioactive Components session.
About the Nutrition 2018 Meeting
At Nutrition 2018, the top scientific researchers, practitioners, global and public health professionals, policy makers and advocacy leaders, industry, media and other related professionals will gather to advance nutrition science and its practical application. Nutrition 2018 offers the latest and best nutrition research, the opportunity to present research, network with peers, and touch and see the latest products and technology in the exhibit hall. Nutrition 2018 is an immersive nutrition experience offering the greatest minds in nutrition science, superior research, interactive exhibits, new technology, and boundless opportunities for networking in a welcoming environment. For more information about the American Society for Nutrition’s inaugural flagship meeting, Nutrition 2018, please visit meeting.nutrition.org.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.
For more information contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): 908-938-1475
E: jenene@jtcir.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
Released April 3, 2018